Form 4: Caris Life Sciences CFO Awarded Significant Restricted Stock Units

Caris Life Sciences, Inc. Chief Financial Officer Luke Thomas Power was awarded 99,321 restricted stock units, increasing his beneficial ownership to 99,571 shares.

Summary

• Luke Thomas Power, Senior Vice President, Chief Financial Officer, and Chief Accounting Officer of Caris Life Sciences, Inc., is the reporting person.
• The transaction date for the acquisition of common stock was June 18, 2025.
• A total of 99,321 shares of common stock were acquired.
• The acquisition price for these shares was $0, as they represent an award of restricted stock units (RSUs).
• The RSUs will vest in accordance with the applicable grant agreement.
• Following this transaction, Luke Thomas Power beneficially owns 99,571 shares of Caris Life Sciences, Inc. common stock.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value and serves as a retention mechanism, though it is not a direct indicator of immediate financial performance.

Positives

• The award of 99,321 restricted stock units to a key executive like the CFO indicates a strong alignment of management's interests with long-term shareholder value.
• Equity awards serve as a retention mechanism for critical talent, ensuring continuity in leadership.
• The increase in the CFO's beneficial ownership suggests confidence in the company's future performance and growth prospects.

Risks

• The full benefit of the restricted stock units to the executive is contingent upon future vesting conditions, which typically include continued employment and may involve performance targets, meaning the shares are not immediately and unconditionally owned.

Future Outlook

The restricted stock units are subject to vesting in accordance with an applicable grant agreement, indicating future milestones related to the executive's equity ownership.

Industry Context

Equity awards, such as Restricted Stock Units (RSUs), are a standard and widely adopted component of executive compensation packages across the biotechnology and life sciences sectors. These awards are crucial for attracting, retaining, and incentivizing key leadership by aligning their financial interests with the long-term performance and strategic objectives of the company.

Comparison to Industry Standards

• The award of RSUs to a Chief Financial Officer is a common practice in the life sciences and technology industries for executive compensation, consistent with strategies employed by peer companies.
• This type of equity grant is comparable to compensation structures seen at companies like Illumina, Guardant Health, or Exact Sciences, which frequently utilize equity-based incentives to motivate leadership and foster alignment with shareholder value creation.
• While the specific size of the grant would typically be benchmarked against compensation data for a defined peer group, such comparative data is not provided within this filing.

Stakeholder Impact

• Shareholders: The transaction enhances the alignment of the CFO's financial interests with shareholder value through increased equity ownership.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• Vesting of the restricted stock units in accordance with the applicable grant agreement.

Key Dates

Keywords

Caris Life Sciences, Luke Thomas Power, Form 4, SEC filing, Restricted Stock Units, RSU, Insider Transaction, CFO, Equity Award, Executive Compensation, Beneficial Ownership